BDSI - バイオデリバリ―・サイエンシズ・インタ―ナショナル （BioDelivery Sciences International Inc.） バイオデリバリ―・サイエンシズ・インタ―ナショナルBDSIのチャート
BDSIの企業情報
| symbol | BDSI |
|---|---|
| 会社名 | BioDelivery Sciences International Inc （バイオデリバリ―・サイエンシズ・インタ―ナショナル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 バイオデリバリ・サイエンシズ・インターナショナル(BioDelivery Sciences International Inc.)は専門製薬会社であり、自社独力或いは第三者との提携で、医療ニーズに応じた治療薬の開発・商業化に従事する。同社は主に疼痛管理とがん補助療法分野向けの医薬品を開発していた。またはそれを開発している。同社は頬粘膜に作用する小・侵食性高分子フィルムである生体侵食性粘膜接着性システム(BEMA)技術を利用して薬品と薬品候補の製剤を行う。同社の米国食品医薬品局（FDA）認可の製品「ONSOLIS」及びその薬品候補のパイプラインはBEMA技術を利用している。 バイオデリバリ―・サイエンシズ・インタ―ナショナルは米国のバイオ医薬品メ―カ―。独自に又は他の医薬品メ―カ―と共同で、実績のある治療薬の新しいアプリケ―ションを開発、製品化。疼痛管理と依存の分野を主とした医薬品を開発。製品を開発する際に、独自開発で特許取得済みの生体内分解性粘膜付着性(BEMA)ドラッグデリバリ―技術を応用する。 |
| 本社所在地 | 4131 ParkLake Avenue Suite 225 Raleigh NC 27612 USA |
| 代表者氏名 | Frank E. O'Donnell フランク・E・オドネル |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 919-582-9050 |
| 設立年月日 | 35431 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 116人 |
| url | www.bdsi.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bdsi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -33.52800 |
| 終値（lastsale） | 3.26 |
| 時価総額（marketcap） | 194162910.5 |
| 時価総額 | 時価総額（百万ドル） 202.50120 |
| 売上高 | 売上高（百万ドル） 47.22100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 196.17320 |
| 当期純利益 | 当期純利益（百万ドル） -48.64000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 BioDelivery Sciences International Inc. revenues decreased 39% to $23.5M. Net loss totaled $20.5M vs. income of $33.4M. Revenues reflect Contract revenues decrease of 95% to $1M Product royalty revenues decrease of 20% to $1.8M Research and development reimbursements decrease from $267K to $0K. Net loss reflects Bargain purchase gain decrease from $27.3M (income) to $0K. |
BDSIのテクニカル分析
BDSIのニュース
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference 2020/11/20 13:30:00 GlobeNewswire
RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical…
BioDelivery Sciences EPS beats by $0.04, revenue in-line (NASDAQ:BDSI) 2020/11/05 13:05:14 Seeking Alpha
BioDelivery Sciences (NASDAQ:BDSI): Q3 GAAP EPS of $0.09 beats by $0.04. Revenue of $39.4M (+30.0% Y/Y) in-line. Press Release
Cancer Pain Market 2020 Size, Share, Industry Insight, Top Key Players BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grnenthal Pharma GmbH 2020/11/04 16:29:40 OpenPR
The global cancer pain market size accounted for $5.53 Billion in 2018 and is projected to reach $7.54 billion by 2025, registering a CAGR of 4.5% during the forecast period. Increase in incidence of cancer worldwide, surge in healthcare expenditure, and
BidaskClub Lowers BioDelivery Sciences International (NASDAQ:BDSI) to Strong Sell 2020/10/25 04:06:46 Stock Observer
BidaskClub downgraded shares of BioDelivery Sciences International (NASDAQ:BDSI) from a sell rating to a strong sell rating in a research report sent to investors on Thursday morning, BidAskClub reports. BDSI has been the subject of a number of other reports. Zacks Investment Research cut shares of BioDelivery Sciences International from a hold rating to a […]
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Receives $7.91 Consensus Target Price from Analysts 2020/10/24 14:40:41 The Olympia Report
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 […]
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference 2020/11/20 13:30:00 GlobeNewswire
RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical…
BioDelivery Sciences EPS beats by $0.04, revenue in-line (NASDAQ:BDSI) 2020/11/05 13:05:14 Seeking Alpha
BioDelivery Sciences (NASDAQ:BDSI): Q3 GAAP EPS of $0.09 beats by $0.04. Revenue of $39.4M (+30.0% Y/Y) in-line. Press Release
Cancer Pain Market 2020 Size, Share, Industry Insight, Top Key Players BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grnenthal Pharma GmbH 2020/11/04 16:29:40 OpenPR
The global cancer pain market size accounted for $5.53 Billion in 2018 and is projected to reach $7.54 billion by 2025, registering a CAGR of 4.5% during the forecast period. Increase in incidence of cancer worldwide, surge in healthcare expenditure, and
BidaskClub Lowers BioDelivery Sciences International (NASDAQ:BDSI) to Strong Sell 2020/10/25 04:06:46 Stock Observer
BidaskClub downgraded shares of BioDelivery Sciences International (NASDAQ:BDSI) from a sell rating to a strong sell rating in a research report sent to investors on Thursday morning, BidAskClub reports. BDSI has been the subject of a number of other reports. Zacks Investment Research cut shares of BioDelivery Sciences International from a hold rating to a […]
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Receives $7.91 Consensus Target Price from Analysts 2020/10/24 14:40:41 The Olympia Report
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 […]
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference 2020/11/20 13:30:00 GlobeNewswire
RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical…
BioDelivery Sciences EPS beats by $0.04, revenue in-line (NASDAQ:BDSI) 2020/11/05 13:05:14 Seeking Alpha
BioDelivery Sciences (NASDAQ:BDSI): Q3 GAAP EPS of $0.09 beats by $0.04. Revenue of $39.4M (+30.0% Y/Y) in-line. Press Release
Cancer Pain Market 2020 Size, Share, Industry Insight, Top Key Players BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grnenthal Pharma GmbH 2020/11/04 16:29:40 OpenPR
The global cancer pain market size accounted for $5.53 Billion in 2018 and is projected to reach $7.54 billion by 2025, registering a CAGR of 4.5% during the forecast period. Increase in incidence of cancer worldwide, surge in healthcare expenditure, and
BidaskClub Lowers BioDelivery Sciences International (NASDAQ:BDSI) to Strong Sell 2020/10/25 04:06:46 Stock Observer
BidaskClub downgraded shares of BioDelivery Sciences International (NASDAQ:BDSI) from a sell rating to a strong sell rating in a research report sent to investors on Thursday morning, BidAskClub reports. BDSI has been the subject of a number of other reports. Zacks Investment Research cut shares of BioDelivery Sciences International from a hold rating to a […]
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Receives $7.91 Consensus Target Price from Analysts 2020/10/24 14:40:41 The Olympia Report
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been assigned a consensus recommendation of “Hold” from the twelve brokerages that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 […]